接受利福平治疗的人类免疫缺陷病毒与结核合并感染患者中依非韦伦每日剂量的体重截断值及基于依非韦伦方案的60周疗效
Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin.
作者信息
Manosuthi Weerawat, Sungkanuparph Somnuek, Tantanathip Preecha, Mankatitham Wiroj, Lueangniyomkul Aroon, Thongyen Supeda, Eampokarap Boonchuay, Uttayamakul Sumonmal, Suwanvattana Pawita, Kaewsaard Samroui, Ruxrungtham Kiat
机构信息
Department of Medicine, Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi 11000, Thailand.
出版信息
Antimicrob Agents Chemother. 2009 Oct;53(10):4545-8. doi: 10.1128/AAC.00492-09. Epub 2009 Aug 10.
Abstract
Seventy-one human immunodeficiency virus-infected patients with tuberculosis who were receiving a rifampin (rifampicin)-containing regimen were initiated on treatment with efavirenz at 600 mg/day plus stavudine-lamivudine. Fasting efavirenz concentrations at 12 h after dosing (C12) were monitored. The mean +/- standard deviation efavirenz C12 at weeks 6 and 12 and after rifampin discontinuation were 4.5 +/- 4.3, 3.8 +/- 3.5, and 3.5 +/- 2.7 mg/liter, respectively. High body weight was associated with a low efavirenz C12 at weeks 6 and 12 (P = 0.003, r = -0.255). The efavirenz C12 regression prediction line at 1 mg/liter intercepted a mean body weight of 57.5 kg.
摘要
71例接受含利福平方案治疗的人类免疫缺陷病毒感染合并结核病患者开始接受依非韦伦600毫克/天联合司他夫定-拉米夫定治疗。监测给药后12小时的空腹依非韦伦浓度（C12）。第6周和第12周以及停用利福平后的依非韦伦C12平均值±标准差分别为4.5±4.3、3.8±3.5和3.5±2.7毫克/升。高体重与第6周和第12周依非韦伦C12较低相关（P = 0.003，r = -0.255）。依非韦伦C12回归预测线在1毫克/升时截距的平均体重为57.5千克。
相似文献
1
Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin.
Antimicrob Agents Chemother. 2009 Oct;53(10):4545-8. doi: 10.1128/AAC.00492-09. Epub 2009 Aug 10.
2
Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
Antimicrob Agents Chemother. 2014 Jun;58(6):3182-90. doi: 10.1128/AAC.02379-13. Epub 2014 Mar 24.
3
A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
Clin Infect Dis. 2009 Jun 15;48(12):1752-9. doi: 10.1086/599114.
4
Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results.
AIDS. 2006 Jan 2;20(1):131-2. doi: 10.1097/01.aids.0000196181.18916.9b.
5
CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1.
Antimicrob Agents Chemother. 2014;58(4):2268-73. doi: 10.1128/AAC.02384-13. Epub 2014 Feb 3.
6
CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India.
Antimicrob Agents Chemother. 2009 Mar;53(3):863-8. doi: 10.1128/AAC.00899-08. Epub 2009 Jan 5.
7
Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy.
PLoS One. 2014 Feb 14;9(2):e88497. doi: 10.1371/journal.pone.0088497. eCollection 2014.
8
Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.
J Antimicrob Chemother. 2017 May 1;72(5):1441-1449. doi: 10.1093/jac/dkx004.
9
The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis.
Eur J Clin Pharmacol. 2012 May;68(5):689-95. doi: 10.1007/s00228-011-1166-5. Epub 2011 Nov 23.
10
Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
Antimicrob Agents Chemother. 2013 Feb;57(2):1019-24. doi: 10.1128/AAC.02023-12. Epub 2012 Dec 17.
引用本文的文献
1
Severe efavirenz associated neurotoxicity: A retrospective cohort study.
S Afr J Infect Dis. 2023 Jul 24;38(1):522. doi: 10.4102/sajid.v38i1.522. eCollection 2023.
2
CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.
BMC Pharmacol Toxicol. 2015 Mar 27;16:4. doi: 10.1186/s40360-015-0004-2.
3
Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy.
PLoS One. 2014 Feb 14;9(2):e88497. doi: 10.1371/journal.pone.0088497. eCollection 2014.
4
CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1.
Antimicrob Agents Chemother. 2014;58(4):2268-73. doi: 10.1128/AAC.02384-13. Epub 2014 Feb 3.
5
Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
Antimicrob Agents Chemother. 2013 Feb;57(2):1019-24. doi: 10.1128/AAC.02023-12. Epub 2012 Dec 17.
6
Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers.
Antimicrob Agents Chemother. 2011 Jul;55(7):3527-33. doi: 10.1128/AAC.00980-10. Epub 2011 Apr 25.
7
Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults.
AIDS Res Ther. 2010 Mar 26;7:8. doi: 10.1186/1742-6405-7-8.
本文引用的文献
1
A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
Clin Infect Dis. 2009 Jun 15;48(12):1752-9. doi: 10.1086/599114.
2
CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India.
Antimicrob Agents Chemother. 2009 Mar;53(3):863-8. doi: 10.1128/AAC.00899-08. Epub 2009 Jan 5.
3
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.
Antivir Ther. 2008;13(5):675-85.
4
Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
HIV Med. 2008 May;9(5):294-9. doi: 10.1111/j.1468-1293.2008.00563.x.
5
Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients.
Curr HIV Res. 2007 May;5(3):349-53. doi: 10.2174/157016207780636588.
6
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.
Clin Pharmacol Ther. 2007 Apr;81(4):557-66. doi: 10.1038/sj.clpt.6100072. Epub 2007 Jan 18.
7
Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.
J Antimicrob Chemother. 2006 Dec;58(6):1299-302. doi: 10.1093/jac/dkl399. Epub 2006 Oct 10.
8
Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents.
Curr HIV/AIDS Rep. 2006 Sep;3(3):118-25. doi: 10.1007/BF02696655.
9
Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results.
AIDS. 2006 Jan 2;20(1):131-2. doi: 10.1097/01.aids.0000196181.18916.9b.
10
Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all.
AIDS. 2005 Sep 23;19(14):1541-3. doi: 10.1097/01.aids.0000183519.45137.a6.
Zotero 插件